CN1658834A - 治疗粘液分泌过多的方法 - Google Patents

治疗粘液分泌过多的方法 Download PDF

Info

Publication number
CN1658834A
CN1658834A CN038129884A CN03812988A CN1658834A CN 1658834 A CN1658834 A CN 1658834A CN 038129884 A CN038129884 A CN 038129884A CN 03812988 A CN03812988 A CN 03812988A CN 1658834 A CN1658834 A CN 1658834A
Authority
CN
China
Prior art keywords
alkyl
group
optional
amino
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038129884A
Other languages
English (en)
Chinese (zh)
Inventor
伯吉特·琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1658834A publication Critical patent/CN1658834A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN038129884A 2002-04-05 2003-04-02 治疗粘液分泌过多的方法 Pending CN1658834A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699 2002-04-05
EP02007699.8 2002-04-05

Publications (1)

Publication Number Publication Date
CN1658834A true CN1658834A (zh) 2005-08-24

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038129884A Pending CN1658834A (zh) 2002-04-05 2003-04-02 治疗粘液分泌过多的方法

Country Status (14)

Country Link
EP (1) EP1494645A2 (ru)
JP (1) JP2005528374A (ru)
KR (1) KR20040101398A (ru)
CN (1) CN1658834A (ru)
AU (1) AU2003224025A1 (ru)
BR (1) BR0309009A (ru)
CA (1) CA2479520A1 (ru)
IL (1) IL163737A0 (ru)
MX (1) MXPA04009605A (ru)
NZ (1) NZ536278A (ru)
PL (1) PL372963A1 (ru)
RU (1) RU2004132847A (ru)
WO (1) WO2003084503A2 (ru)
ZA (1) ZA200406910B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2903774B1 (fr) * 2006-07-17 2008-09-05 Renault Sas Procede de validation d'un diagnostic de fontionnement d'un dispositif.
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
WO2010067131A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
NZ514711A (en) * 1999-03-12 2004-02-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
ATE376547T1 (de) * 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
CN1304375C (zh) * 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
BR0014041A (pt) * 1999-09-17 2003-07-15 Smithkline Beecham Corp Utilização de csaids em infecção por rinovìrus
CN100355750C (zh) * 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
JP2004511542A (ja) * 2000-10-19 2004-04-15 スミスクライン・ビーチャム・コーポレイション 煙の吸入の治療のためのｐ３８阻害剤の使用
EP1381594A1 (en) * 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. Urea compounds useful as anti-inflammatory agents
TR200401028T2 (tr) * 2001-11-09 2004-11-22 Scios Inc. Kistik fibrozun tedavisine yönelik metot

Also Published As

Publication number Publication date
NZ536278A (en) 2007-05-31
BR0309009A (pt) 2005-03-22
CA2479520A1 (en) 2003-10-16
JP2005528374A (ja) 2005-09-22
RU2004132847A (ru) 2006-08-20
EP1494645A2 (en) 2005-01-12
ZA200406910B (en) 2006-06-28
AU2003224025A1 (en) 2003-10-20
PL372963A1 (en) 2005-08-08
MXPA04009605A (es) 2005-01-11
WO2003084503A2 (en) 2003-10-16
WO2003084503A3 (en) 2004-04-08
KR20040101398A (ko) 2004-12-02
IL163737A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CN1658873A (zh) 基于抗胆碱能剂和p38激酶抑制剂的新颖药物组合物
CN1297555C (zh) Mcp－1功能的拮抗物及其使用方法
CN1242995C (zh) 化合物,它们的用途和制备方法
CN1324012C (zh) TNF－α生成抑制剂
CN1301973C (zh) 杂环衍生物及医药品
CN1215069C (zh) 调整内皮肽活性的磺酰胺及其衍生物
CN1282640C (zh) N－芳基苯乙酰胺衍生物及包含所述化合物的药物组合物
CN1751038A (zh) 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
CN1917882A (zh) 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
CN1189467C (zh) 药学活性磺酰胺衍生物
CN1658834A (zh) 治疗粘液分泌过多的方法
CN1633294A (zh) 2,4,5－三取代噻唑衍生物和它们的抗炎活性
CN1652779A (zh) 化学激活物中介的疾病的结合治疗
CN1933838A (zh) 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
CN1803795A (zh) 用作抗变态反应药物的哌啶化合物
CN1444573A (zh) 甲酰胺化合物及其作为人11cby受体拮抗剂的用途
CN1439010A (zh) 吡咯并[2,3－d]嘧啶化合物作为免疫抑制剂
CN1826120A (zh) 用于发炎与免疫相关用途的化合物
CN1575283A (zh) 具有ccr1受体拮抗剂活性的哌嗪衍生物
CN1256324C (zh) 用作Xa因子抑制剂的吡咯烷衍生物
CN1890238A (zh) 作为人orl1受体的激动剂的氢诺卜醇衍生物
CN1114591C (zh) 环酰胺化合物
CN101056631A (zh) 治疗阿片类成瘾的芳基（或杂芳基）唑基甲醇衍生物
CN1771237A (zh) 在治疗血栓栓塞性疾病中用作凝血因子 x a抑制剂的 1 － (苯基氨基甲酰基 ) － 2 － ( 4 － ( 3 －氧代－吗啉 － 4－基 ) －苯基氨基甲酰基)吡咯烷衍生物及相关化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080740

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080740

Country of ref document: HK